[
  {
    "ts": null,
    "headline": "LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal",
    "summary": "Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.",
    "url": "https://finnhub.io/api/news?id=65093b8b993df8431d20cce861c53b55126dfd73614337c2192cc05544d3487c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757435640,
      "headline": "LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal",
      "id": 136688671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.",
      "url": "https://finnhub.io/api/news?id=65093b8b993df8431d20cce861c53b55126dfd73614337c2192cc05544d3487c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
    "summary": "Get key takeaways from AbbVie's 2025 Morgan Stanley Healthcare Conferenceâpolicy insights,",
    "url": "https://finnhub.io/api/news?id=ccc9e2afca990a284be9f6955bb21a92eb2759a8509c87750afb27ebd360c46b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757425563,
      "headline": "AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)",
      "id": 136678304,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Get key takeaways from AbbVie's 2025 Morgan Stanley Healthcare Conferenceâpolicy insights,",
      "url": "https://finnhub.io/api/news?id=ccc9e2afca990a284be9f6955bb21a92eb2759a8509c87750afb27ebd360c46b"
    }
  },
  {
    "ts": null,
    "headline": "BOTOX® Cosmetic (onabotulinumtoxinA) Unveils \"The One & Only\" Campaign Featuring Real People and Their Distinctive Stories",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced a new chapter for BOTOX® Cosmetic with the debut of \"The One & Only\" campaign, a national, multichannel marketing initiative that champions self-expression and individuality. The one and only brand to do it first, BOTOX® Cosmetic is the #1 selling neurotoxin worldwide with the most FDA-approved aesthetic indication areas in the category, empowering patients to embrace the one and only version of themselves.2,4-9",
    "url": "https://finnhub.io/api/news?id=e5f9b0860d459ac01ed0877ea92754136d8b4079dd2d32d423f4a515e2c49d69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757422800,
      "headline": "BOTOX® Cosmetic (onabotulinumtoxinA) Unveils \"The One & Only\" Campaign Featuring Real People and Their Distinctive Stories",
      "id": 136688718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced a new chapter for BOTOX® Cosmetic with the debut of \"The One & Only\" campaign, a national, multichannel marketing initiative that champions self-expression and individuality. The one and only brand to do it first, BOTOX® Cosmetic is the #1 selling neurotoxin worldwide with the most FDA-approved aesthetic indication areas in the category, empowering patients to embrace the one and only version of themselves.2,4-9",
      "url": "https://finnhub.io/api/news?id=e5f9b0860d459ac01ed0877ea92754136d8b4079dd2d32d423f4a515e2c49d69"
    }
  }
]